Celdoxome pegylated liposomal 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
PSUSA/1172/
Periodic Safety Update EU Single assessment - 
22/06/2023 
23/08/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
202211 
doxorubicin 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/1172/202211. 
IA/0003 
B.II.b.5.c - Change to in-process tests or limits 
08/08/2023 
n/a 
applied during the manufacture of the finished 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
product - Deletion of a non-significant in-process test 
IAIN/0002 
A.1 - Administrative change - Change in the name 
13/04/2023 
23/08/2023 
SmPC, 
and/or address of the MAH 
Labelling and 
PL 
Page 2/2 
 
 
 
 
 
 
 
 
 
